BlackRock’s Senti Biosciences Holdings SNTI Stock Holding History

BlackRock’s Portfolio SNTI Stock Details SNTI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.4K	Sell	4,004 -21,070	-84%	-$20.6K	﹤0.01%	5501
2026 Q1	$20.4K	Buy	25,074 +1,690	+7%	+$1.64K	﹤0.01%	5299
2025 Q4	$24.3K	Buy	23,384 +780	+3%	+$1.38K	﹤0.01%	5181
2025 Q3	$31.9K	Buy	22,604 +520	+2%	+$869	﹤0.01%	5061
2025 Q2	$46.6K	Buy	22,084 +18,080	+452%	+$57.2K	﹤0.01%	5000
2025 Q1	$13.5K	Hold	4,004	–	–	﹤0.01%	5141
2024 Q4	$14.1K	Hold	4,004	–	–	﹤0.01%	5144
2024 Q3	$9.05K	Sell	4,004 -1	-0%	-$3	﹤0.01%	4989
2024 Q2	$11.1K	Hold	4,005	–	–	﹤0.01%	5061
2024 Q1	$15.1K	Hold	4,005	–	–	﹤0.01%	5051
2023 Q4	$26.4K	Hold	4,005	–	–	﹤0.01%	5050
2023 Q3	$16.5K	Hold	4,005	–	–	﹤0.01%	5164
2023 Q2	$25.1K	Hold	4,005	–	–	﹤0.01%	5176
2023 Q1	$47.3K	Hold	4,005	–	–	﹤0.01%	5132
2022 Q4	$56.5K	Buy	4,005 +3,742	+1,423%	+$91.3K	﹤0.01%	5194
2022 Q3	$6K	Buy	+263	New	+$5.18K	﹤0.01%	5623

Other funds holding SNTI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

MVM

Menlo Ventures Management Menlo Park, California $357M AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

BlackRock's SNTI Position: Q2 2026 in Review

BlackRock reduced its Senti Biosciences Holdings (SNTI) stake by 84% in Q2 2026, selling an estimated $20.6K and leaving 4,004 shares worth $4.4K. The position accounts for ﹤0.01% of the portfolio, ranked #5501.

BlackRock first reported a position in SNTI in Q3 2022 and has held it in 16 quarters since. The position peaked at $56.5K in Q4 2022. 19 funds tracked by Wall St. Rank hold SNTI as of Q2 2026.

BlackRock held 4,004 shares of Senti Biosciences Holdings worth $4.4K as of Q2 2026.
BlackRock sold 21,070 Senti Biosciences Holdings shares in Q2 2026, an estimated $20.6K.
Senti Biosciences Holdings made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5501 holding.
BlackRock first reported a position in Senti Biosciences Holdings in Q3 2022 and has held it in 16 quarters since.
BlackRock's Senti Biosciences Holdings position peaked at $56.5K in Q4 2022.
19 funds tracked by Wall St. Rank held Senti Biosciences Holdings as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.